D. Aletaha, J. Funovits, and E. C. Keystone, Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients, Arthritis Rheum, vol.56, pp.3226-3261, 2007.

A. A. Den-broeder, A. Van-der-maas, . Van-den-bemt, and . Bj, Dose deescalation strategies and role of therapeutic drug monitoring of biologics in RA, Rheumatology, vol.49, pp.1801-1804, 2010.

M. Nawata, K. Saito, and S. Nakayamada, Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission, Mod Rheumatol, vol.18, pp.460-464, 2008.

O. Brocq, E. Millasseau, and C. Albert, Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis, Joint Bone Spine, vol.76, pp.350-355, 2009.

Y. Tanaka, T. Takeuchi, and T. Mimori, Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study, Ann Rheum Dis, vol.69, pp.1286-91, 2010.

A. Van-der-maas, W. Kievit, and B. J. Van-den-bemt, Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study, Ann Rheum Dis, vol.71, pp.1849-54, 2012.

N. Nishimoto, K. Amano, and Y. Hirabayashi, Drug free remission/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) study, Modern Rheumatology, vol.24, pp.17-25, 2014.

J. S. Smolen, P. Nash, and P. Durez, Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial, Lancet, vol.381, pp.918-947, 2013.

A. A. Den-broeder, N. Van-herwaarden, and A. Van-der-maas, Dose reduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study, BMC Musculoskelet Disord, vol.14, p.299, 2013.

N. Van-herwaarden, A. Van-der-maas, and M. J. Minten, Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial, BMJ, vol.350, p.1389, 2015.

L. M. Verhoef, L. Tweehuysen, and M. E. Hulscher, bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search, Rheumatol Ther, vol.4, pp.1-24, 2017.

C. A. Bouman, N. Van-herwaarden, and F. Van-den-hoogen, Longterm outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study -a randomised controlled pragmatic non-inferiority strategy trial, Ann Rheum Dis, 2017.

B. Raffeiner, C. Botsios, and F. Ometto, Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose, Clin Exp Rheumatol, vol.33, pp.63-71, 2015.

B. Fautrel, T. Pham, and T. Alfaiate, Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study), Ann Rheum Dis, vol.75, pp.59-67, 2016.

M. Prevoo, &. Van, M. A. Hof, and H. H. Kuper, Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, vol.38, pp.44-52, 1995.

F. C. Arnett, S. M. Edworthy, and D. A. Bloch, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, vol.31, pp.315-339, 1988.

D. E. Furst, S. A. Shaikh, and M. Greenwald, Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis, Arthritis Care Res, vol.67, pp.151-60, 2015.

R. F. Van-vollenhoven, M. Østergaard, and M. Leirisalo-repo, Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis, Ann Rheum Dis, vol.75, pp.52-60, 2016.

J. Kaine, G. Gladstein, and I. Strusberg, Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study), Ann Rheum Dis, vol.71, pp.38-44, 2012.

K. Bendtzen, P. Geborek, and M. Svenson, Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab, Arthritis Rheum, vol.54, pp.3782-3791, 2006.

G. J. Wolbink, M. Vis, and W. Lems, Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis Rheum, vol.54, pp.711-716, 2006.

G. M. Bartelds, C. A. Wijbrandts, and M. T. Nurmohamed, Antiinfliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study, Ann Rheum Dis, vol.69, pp.817-838, 2010.

G. M. Bartelds, C. A. Wijbrandts, and M. T. Nurmohamed, Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis, Ann Rheum Dis, vol.66, pp.921-927, 2007.

A. Jamnitski, C. L. Krieckaert, and M. T. Nurmohamed, Patients nonresponding to etanercept obtain lower etanercept concentrations compared with responding patients, Ann Rheum Dis, vol.71, pp.88-91, 2012.

C. O. Bingham, A. M. Mendelsohn, and L. Kim, Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: week-112 efficacy and safety results of the open-label longterm extension of a phase III, double-blind, randomized, placebocontrolled trial, Arthritis Care Res, vol.67, pp.1627-1663, 2015.

J. Sigaux, M. Hamze, and C. Daien, Immunogenicity of tocilizumab in patients with rheumatoid arthritis, Joint Bone Spine, vol.84, pp.39-45, 2017.

S. Lillegraven, F. H. Prince, and N. A. Shadick, Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort, copyright. on October, vol.71, pp.681-687, 2012.